CEO: Joseph Gardner
Headquarters: Cincinnati, Ohio
Investment Date: March 2017
APO Financing: $40,500,000
Trading Venue: NASDAQ CM (ARPO)
Aerpio Therapeutics: Is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The lead programs include a Tie2 activator for diabetic retinopathy (DR) and a hypoxia-inducible factor α (HIF-α) stabilizer for the treatment of inflammatory bowel disease. The lead compound for the Tie2 program, AKB-9778, recently completed a proof-of-concept, Phase 2a study (TIME-2). AKB-4924, the lead compound in our HIF-α stabilization program, has recently completed a Phase 1a study.